{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:33:28Z","timestamp":1791909208565,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11427-024-2722-2","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:02:22Z","timestamp":1729317742000},"page":"541-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Epidemiology of liver diseases: global disease burden and forecasted research trends"],"prefix":"10.1007","volume":"68","author":[{"given":"Jia","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodi","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2722_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000899","volume-title":"Hepatology","author":"F \u00c5berg","year":"2024","unstructured":"\u00c5berg, F., Jiang, Z.G., Cortez-Pinto, H., and M\u00e4nnist\u00f6, V. (2024). Alcohol-associated liver disease\u2014Global epidemiology. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000899."},{"key":"2722_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade, R.J., Chalasani, N., Bj\u00f6rnsson, E.S., Suzuki, A., Kullak-Ublick, G.A., Watkins, P.B., Devarbhavi, H., Merz, M., Lucena, M.I., Kaplowitz, N., et al. (2019). Drug-induced liver injury. Nat Rev Dis Primers 5, 58.","journal-title":"Nat Rev Dis Primers"},{"key":"2722_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani, S.K., Devarbhavi, H., Eaton, J., and Kamath, P.S. (2019). Burden of liver diseases in the world. J Hepatol 70, 151\u2013171.","journal-title":"J Hepatol"},{"key":"2722_CR4","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.31583","volume":"73","author":"SK Asrani","year":"2021","unstructured":"Asrani, S.K., Mellinger, J., Arab, J.P., and Shah, V.H. (2021). Reducing the global burden of alcohol-associated liver disease: a blueprint for action. Hepatology 73, 2039\u20132050.","journal-title":"Hepatology"},{"key":"2722_CR5","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani, M., Sardh, E., Ventura, P., Peir\u00f3, P.A., Rees, D.C., St\u00f6lzel, U., Bissell, D.M., Bonkovsky, H.L., Windyga, J., Anderson, K.E., et al. (2020). Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med 382, 2289\u20132301.","journal-title":"N Engl J Med"},{"key":"2722_CR6","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.molmed.2021.06.007","volume":"27","author":"P Brescia","year":"2021","unstructured":"Brescia, P., and Rescigno, M. (2021). The gut vascular barrier: a new player in the gut\u2013liver\u2013brain axis. Trends Mol Med 27, 844\u2013855.","journal-title":"Trends Mol Med"},{"key":"2722_CR7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","volume":"27","author":"RA Calle","year":"2021","unstructured":"Calle, R.A., Amin, N.B., Carvajal-Gonzalez, S., Ross, T.T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021). ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med 27, 1836\u20131848.","journal-title":"Nat Med"},{"key":"2722_CR8","unstructured":"Editor, ed. (2023). Report on Hepatitis B and C Surveillance in Canada: 2019. Public Health Agency of Canada, 2022."},{"key":"2722_CR9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2022.06.005","volume":"77","author":"P Carrieri","year":"2022","unstructured":"Carrieri, P., Barr\u00e9, T., Bureau, M., Marcellin, F., and Mourad, A. (2022). Stigma and care avoidance in people with unhealthy alcohol use: a call for research and action. J Hepatol 77, 1221\u20131222.","journal-title":"J Hepatol"},{"key":"2722_CR10","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.cmet.2023.05.012","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew, N.W.S., Ng, C.H., Tan, D.J.H., Huang, D.Q., and Muthiah, M.D. (2023a). Response to Paik et al. on the disease burden of NAFLD. Cell Metab 35, 1089\u20131090.","journal-title":"Cell Metab"},{"key":"2722_CR11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew, N.W.S., Ng, C.H., Tan, D.J.H., Kong, G., Lin, C., Chin, Y.H., Lim, W.H., Huang, D.Q., Quek, J., Fu, C.E., et al. (2023b). The global burden of metabolic disease: data from 2000 to 2019. Cell Metab 35, 414\u2013428.e3.","journal-title":"Cell Metab"},{"key":"2722_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"SG Sepanlou","year":"2020","unstructured":"Sepanlou, S.G., Safiri, S., Bisignano, C., Ikuta, K.S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D.V., Abdoli, A., et al. (2020a). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5, 245\u2013266.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2722_CR13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos, T., Lim, S.S., Abbafati, C., Abbas, K.M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020b). Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204\u20131222.","journal-title":"Lancet"},{"key":"2722_CR14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"BS Sheena","year":"2022","unstructured":"Sheena, B.S., Hiebert, L., Han, H., Ippolito, H., Abbasi-Kangevari, M., Abbasi-Kangevari, Z., Abbastabar, H., Abdoli, A., Abubaker Ali, H., Adane, M.M., et al. (2022). Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol 7, 796\u2013829.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2722_CR15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"D Razavi-Shearer","year":"2023","unstructured":"Razavi-Shearer, D., Gamkrelidze, I., Pan, C., Jia, J., Berg, T., Gray, R., Lim, Y.S., Chen, C.J., Ocama, P., Desalegn, H., et al. (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol 8, 879\u2013907.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2722_CR16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S2468-1253(23)00321-7","volume":"9","author":"GS Cooke","year":"2024","unstructured":"Cooke, G.S., Flower, B., Cunningham, E., Marshall, A.D., Lazarus, J.V., Palayew, A., Jia, J., Aggarwal, R., Al-Mahtab, M., Tanaka, Y., et al. (2024). Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update. Lancet Gastroenterol Hepatol 9, 346\u2013365.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2722_CR17","doi-asserted-by":"crossref","first-page":"e43089","DOI":"10.2196\/43089","volume":"24","author":"O Delardas","year":"2022","unstructured":"Delardas, O., and Giannos, P. (2022). How COVID-19 affected the journal impact factor of high impact medical journals: bibliometric analysis. J Med Internet Res 24, e43089.","journal-title":"J Med Internet Res"},{"key":"2722_CR18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmet.2017.01.006","volume":"25","author":"S Della Torre","year":"2017","unstructured":"Della Torre, S., and Maggi, A. (2017). Sex differences: a resultant of an evolutionary pressure? Cell Metab 25, 499\u2013505.","journal-title":"Cell Metab"},{"key":"2722_CR19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H., Asrani, S.K., Arab, J.P., Nartey, Y.A., Pose, E., and Kamath, P.S. (2023). Global burden of liver disease: 2023 update. J Hepatol 79, 516\u2013537.","journal-title":"J Hepatol"},{"key":"2722_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41575-020-00392-3","volume":"18","author":"GJ Dore","year":"2021","unstructured":"Dore, G.J., and Bajis, S. (2021). Hepatitis C virus elimination: laying the foundation for achieving 2030 targets. Nat Rev Gastroenterol Hepatol 18, 91\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. (2016). EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64, 433\u2013485. doi: https:\/\/doi.org\/10.1016\/j.jhep.2015.10.006.","journal-title":"J Hepatol"},{"key":"2722_CR22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","volume":"17","author":"F Tacke","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), Tacke, F., Horn, P., Wong, V.W., Ratziu, V., Bugianesi, E., Francque, S., Valenti, L., et al. (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts 17, 374\u2013444.","journal-title":"Obes Facts"},{"key":"2722_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41575-021-00570-x","volume":"19","author":"MH El-Sayed","year":"2022","unstructured":"El-Sayed, M.H., and Feld, J.J. (2022). Vaccination at the forefront of the fight against hepatitis B and C. Nat Rev Gastroenterol Hepatol 19, 87\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes, C., Anstee, Q.M., Arias-Loste, M.T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C.P., et al. (2018). Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 69, 896\u2013904.","journal-title":"J Hepatol"},{"key":"2722_CR25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","volume":"2","author":"A Facciorusso","year":"2017","unstructured":"Facciorusso, A., Chandar, A.K., Murad, M.H., ProkoP, L.J., Muscatiello, N., Kamath, P. S., and Singh, S. (2017). Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2, 94\u2013102.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2722_CR26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D.R., Higdon, M.M., Abu-Raddad, L.J., Andrews, N., Araos, R., Goldberg, Y., Groome, M.J., Huppert, A., O\u2019Brien, K.L., Smith, P.G., et al. (2022). Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944.","journal-title":"Lancet"},{"key":"2722_CR27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng, G., Valenti, L., Wong, V.W.S., Fouad, Y.M., Yilmaz, Y., Kim, W., Sebastiani, G., Younossi, Z.M., Hernandez-Gea, V., and Zheng, M.H. (2024). Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 21, 46\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR28","doi-asserted-by":"crossref","first-page":"102521","DOI":"10.1016\/j.ajp.2020.102521","volume":"56","author":"S Grover","year":"2021","unstructured":"Grover, S., Gupta, B.M., and Dhawan, S.M. (2021). Schizophrenia research in India: a scientometric assessmentof India\u2019s publications during 1990\u20132019. Asian J Psychiatry 56, 102521.","journal-title":"Asian J Psychiatry"},{"key":"2722_CR29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S.A., Bedossa, P., Guy, C.D., Schattenberg, J.M., Loomba, R., Taub, R., Labriola, D., Moussa, S.E., Neff, G.W., Rinella, M.E., et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390, 497\u2013509.","journal-title":"N Engl J Med"},{"key":"2722_CR30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach, J.K., Kulik, L.M., Finn, R.S., Sirlin, C.B., Abecassis, M.M., Roberts, L.R., Zhu, A.X., Murad, M.H., and Marrero, J.A. (2018). AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358\u2013380.","journal-title":"Hepatology"},{"key":"2722_CR31","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister, M.G., Rosenthal, E.M., Barker, L.K., Rosenberg, E.S., Barranco, M.A., Hall, E.W., Edlin, B.R., Mermin, J., Ward, J.W., and Ryerson, A.B. (2019). Estimating prevalence of hepatitis C virus infection in the united states, 2013\u20132016. Hepatology 69, 1020\u20131031.","journal-title":"Hepatology"},{"key":"2722_CR32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu, Y.C., Huang, D.Q., and Nguyen, M.H. (2023). Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol 20, 524\u2013537.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.31649","volume":"74","author":"GN Ioannou","year":"2021","unstructured":"Ioannou, G.N., Liang, P.S., Locke, E., Green, P., Berry, K., O\u2019Hare, A.M., Shah, J.A., Crothers, K., Eastment, M.K.C., Fan, V.S., et al. (2021). Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US veterans: risk of infection, hospitalization, ventilation, and mortality. Hepatology 74, 322\u2013335.","journal-title":"Hepatology"},{"key":"2722_CR34","first-page":"7","volume-title":"Hepatol Commun","author":"WJ Jeng","year":"2023","unstructured":"Jeng, W.J., and Lok, A.S.F. (2023). What will it take to cure hepatitis B? Hepatol Commun 7."},{"key":"2722_CR35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12911-021-01501-1","volume":"21","author":"SC Johnson","year":"2021","unstructured":"Johnson, S.C., Cunningham, M., Dippenaar, I.N., Sharara, F., Wool, E.E., Agesa, K.M., Han, C., Miller-Petrie, M.K., Wilson, S., Fuller, J.E., et al. (2021). Public health utility of cause of death data: applying empirical algorithms to improve data quality. BMC Med Inform Decis Mak 21, 175.","journal-title":"BMC Med Inform Decis Mak"},{"key":"2722_CR36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2020.06.006","volume":"73","author":"D Jothimani","year":"2020","unstructured":"Jothimani, D., Venugopal, R., Abedin, M.F., Kaliamoorthy, I., and Rela, M. (2020). COVID-19 and the liver. J Hepatol 73, 1231\u20131240.","journal-title":"J Hepatol"},{"key":"2722_CR37","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2021.08.050","volume":"161","author":"WR Kim","year":"2021","unstructured":"Kim, W.R., Mannalithara, A., Heimbach, J.K., Kamath, P.S., Asrani, S.K., Biggins, S. W., Wood, N.L., Gentry, S.E., and Kwong, A.J. (2021). MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology 161, 1887\u20131895.e4.","journal-title":"Gastroenterology"},{"key":"2722_CR38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021). Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10, 181\u2013223.","journal-title":"Liver Cancer"},{"key":"2722_CR39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J.V., Mark, H.E., Anstee, Q.M., Arab, J.P., Batterham, R.L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M.A., et al. (2022). Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 19, 60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR40","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.cgh.2020.08.047","volume":"19","author":"W Li","year":"2021","unstructured":"Li, W., Kemos, P., Salciccioli, J.D., Marshall, D.C., Shalhoub, J., and Alazawi, W. (2021). Socioeconomic factors associated with liver-related mortality from 1985 to 2015 in 36 developed countries. Clin Gastroenterol Hepatol 19, 1698\u20131707.e13.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2722_CR41","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","volume":"115","author":"JK Lim","year":"2020","unstructured":"Lim, J.K., Nguyen, M.H., Kim, W.R., Gish, R., Perumalswami, P., and Jacobson, I.M. (2020). Prevalence of chronic hepatitis B virus infection in the United States. Am J Gastroenterol 115, 1429\u20131438.","journal-title":"Am J Gastroenterol"},{"key":"2722_CR42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim, S.G., Baumert, T.F., Boni, C., Gane, E., Levrero, M., Lok, A.S., Maini, M.K., Terrault, N.A., and Zoulim, F. (2023). The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol 20, 238\u2013253.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR43","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cam4.4551","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Zheng, J., Hao, J., Wang, R.R., Liu, X., Gu, P., Yu, H., Yu, Y., Wu, C., Ou, B., et al. (2022). Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med 11, 1310\u20131323.","journal-title":"Cancer Med"},{"key":"2722_CR44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., and Finn, R.S. (2021). Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6.","journal-title":"Nat Rev Dis Primers"},{"key":"2722_CR45","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D.L., Win, S., Than, T.A., Abdelmalek, M.F., and Suzuki, A. (2019). Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 70, 1457\u20131469.","journal-title":"Hepatology"},{"key":"2722_CR46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba, R., Abdelmalek, M.F., Armstrong, M.J., Jara, M., Kj\u00e6r, M.S., KraruP, N., Lawitz, E., Ratziu, V., Sanyal, A.J., Schattenberg, J.M., et al. (2023). Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8, 511\u2013522.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2722_CR47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R., Hartman, M.L., Lawitz, E.J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O.W., Tang, Y., et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391, 299\u2013310.","journal-title":"N Engl J Med"},{"key":"2722_CR48","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.14309\/ajg.0000000000001292","volume":"116","author":"C Ma","year":"2021","unstructured":"Ma, C., Qian, A.S., Nguyen, N.H., Stukalin, I., Congly, S.E., Shaheen, A.A., Swain, M. G., Teriaky, A., Asrani, S.K., and Singh, S. (2021). Trends in the economic burden of chronic liver diseases and cirrhosis in the United States: 1996\u20132016. Am J Gastroenterol 116, 2060\u20132067.","journal-title":"Am J Gastroenterol"},{"key":"2722_CR49","doi-asserted-by":"crossref","first-page":"e176345","DOI":"10.1172\/JCI176345","volume":"134","author":"B Mackowiak","year":"2024","unstructured":"Mackowiak, B., Fu, Y., Maccioni, L., and Gao, B. (2024). Alcohol-associated liver disease. J Clin Invest 134, e176345.","journal-title":"J Clin Invest"},{"key":"2722_CR50","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jgh.13995","volume":"33","author":"R Mahajan","year":"2018","unstructured":"Mahajan, R., Midha, V., Goyal, O., Mehta, V., Narang, V., Kaur, K., Singh, A., Singh, D., Bhanot, R., and Sood, A. (2018). Clinical profile of hepatitis C virus infection in a developing country: India. J Gastro Hepatol 33, 926\u2013933.","journal-title":"J Gastro Hepatol"},{"key":"2722_CR51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns, M.P., and Maasoumy, B. (2022). Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol 19, 533\u2013550.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2020.09.024","volume":"74","author":"T Marjot","year":"2021","unstructured":"Marjot, T., Moon, A.M., Cook, J.A., Abd-Elsalam, S., Aloman, C., Armstrong, M.J., Pose, E., Brenner, E.J., Cargill, T., Catana, M.A., et al. (2021). Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 74, 567\u2013577.","journal-title":"J Hepatol"},{"key":"2722_CR53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao, L., Targher, G., Byrne, C.D., Cao, Y.Y., and Zheng, M.H. (2024). Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 35, 697\u2013707.","journal-title":"Trends Endocrinol Metab"},{"key":"2722_CR54","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.cgh.2019.10.017","volume":"18","author":"T Mitchell","year":"2020","unstructured":"Mitchell, T., McKinnon, E., Ayonrinde, O., Adams, L.A., Trinder, D., Chua, A.C.G., Newton, R.U., Straker, L., and Olynyk, J.K. (2020). Decreased physical working capacity in adolescents with nonalcoholic fatty liver disease associates with reduced iron availability. Clin Gastroenterol Hepatol 18, 1584\u20131591.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2722_CR55","first-page":"e0251","volume":"7","author":"JM Paik","year":"2023","unstructured":"Paik, J.M., Henry, L., Younossi, Y., Ong, J., Alqahtani, S., and Younossi, Z.M. (2023a). The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 7, e0251.","journal-title":"Hepatol Commun"},{"key":"2722_CR56","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cmet.2023.06.012","volume":"35","author":"JM Paik","year":"2023","unstructured":"Paik, J.M., Henry, L., and Younossi, Z.M. (2023b). Nonalcoholic fatty liver disease mortality may not be decreasing: a need for careful interpretation of GBD 2019 estimates of liver deaths. Cell Metab 35, 1087\u20131088.","journal-title":"Cell Metab"},{"key":"2722_CR57","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","volume":"75","author":"JM Paik","year":"2022","unstructured":"Paik, J.M., Kabbara, K., Eberly, K.E., Younossi, Y., Henry, L., and Younossi, Z.M. (2022). Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology 75, 1204\u20131217.","journal-title":"Hepatology"},{"key":"2722_CR58","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","volume":"44","author":"S Petta","year":"2024","unstructured":"Petta, S., Targher, G., Romeo, S., Pajvani, U.B., Zheng, M., Aghemo, A., and Valenti, L.V.C. (2024). The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int 44, 1526\u20131536.","journal-title":"Liver Int"},{"key":"2722_CR59","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s40265-023-01939-9","volume":"83","author":"DS Prince","year":"2023","unstructured":"Prince, D.S., Nash, E., and Liu, K. (2023). Alcohol-associated liver disease: evolving concepts and treatments. Drugs 83, 1459\u20131474.","journal-title":"Drugs"},{"key":"2722_CR60","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2468-2667(20)30052-9","volume":"5","author":"C Probst","year":"2020","unstructured":"Probst, C., Kilian, C., Sanchez, S., Lange, S., and Rehm, J. (2020). The role of alcohol use and drinking patterns in socioeconomic inequalities in mortality: a systematic review. Lancet Public Health 5, e324\u2013e332.","journal-title":"Lancet Public Health"},{"key":"2722_CR61","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S., Chen, M., Cheng, A.L., Kaseb, A.O., Kudo, M., Lee, H.C., YopP, A.C., Zhou, J., Wang, L., Wen, X., et al. (2023). Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1835\u20131847.","journal-title":"Lancet"},{"key":"2722_CR62","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., Romero, D., Abdelmalek, M.F., Anstee, Q.M., Arab, J.P., et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79, 1542\u20131556.","journal-title":"J Hepatol"},{"key":"2722_CR63","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0140-6736(13)61046-6","volume":"382","author":"JA R\u00f8ttingen","year":"2013","unstructured":"R\u00f8ttingen, J.A., Regmi, S., Eide, M., Young, A.J., Viergever, R.F., \u00c5rdal, C., Guzman, J., Edwards, D., Matlin, S.A., and Terry, R.F. (2013). Mapping of available health research and development data: what\u2019s there, what\u2019s missing, and what role is there for a global observatory? Lancet 382, 1286\u20131307.","journal-title":"Lancet"},{"key":"2722_CR64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41575-022-00607-9","volume":"19","author":"FP Russo","year":"2022","unstructured":"Russo, F.P., Burra, P., and Zanetto, A. (2022). COVID-19 and liver disease: where are we now? Nat Rev Gastroenterol Hepatol 19, 277\u2013278.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR65","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.31425","volume":"72","author":"MW Russo","year":"2020","unstructured":"Russo, M.W., Fix, O.K., Koteish, A.A., Duggan, K., Ditmyer, M., Fuchs, M., Chung, R. T., and Reddy, G. (2020). Modeling the hepatology workforce in the United States: a predicted critical shortage. Hepatology 72, 1444\u20131454.","journal-title":"Hepatology"},{"key":"2722_CR66","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E.N., Furuse, J., Kang, Y.K., et al. (2024). Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol 35, 448\u2013457.","journal-title":"Ann Oncol"},{"key":"2722_CR67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A.J., Bedossa, P., Fraessdorf, M., Neff, G.W., Lawitz, E., Bugianesi, E., Anstee, Q.M., Hussain, S.A., Newsome, P.N., Ratziu, V., et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391, 311\u2013319.","journal-title":"N Engl J Med"},{"key":"2722_CR68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00281-018-0715-8","volume":"41","author":"D Schwinge","year":"2019","unstructured":"Schwinge, D., and Schramm, C. (2019). Sex-related factors in autoimmune liver diseases. Semin Immunopathol 41, 165\u2013175.","journal-title":"Semin Immunopathol"},{"key":"2722_CR69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","volume":"4","author":"HK Seitz","year":"2018","unstructured":"Seitz, H.K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., and Tsukamoto, H. (2018). Alcoholic liver disease. Nat Rev Dis Primers 4, 16.","journal-title":"Nat Rev Dis Primers"},{"key":"2722_CR70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cld.168","volume":"2","author":"AK Singal","year":"2013","unstructured":"Singal, A.K., and Anand, B.S. (2013). Recent trends in the epidemiology of alcoholic liver disease. Clin Liver Dis 2, 53\u201356.","journal-title":"Clin Liver Dis"},{"key":"2722_CR71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan, N., H\u00e4ring, H.U., and Cusi, K. (2019). Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7, 313\u2013324.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2722_CR72","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke, F., Puengel, T., Loomba, R., and Friedman, S.L. (2023). An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol 79, 552\u2013566.","journal-title":"J Hepatol"},{"key":"2722_CR73","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/nu15224765","volume":"15","author":"FC Tang","year":"2023","unstructured":"Tang, F.C., Li, R.H., and Huang, J.H. (2023). Unraveling the connection between fatty liver severity with gender, lifestyle, and health risks among workers. Nutrients 15, 4765.","journal-title":"Nutrients"},{"key":"2722_CR74","doi-asserted-by":"crossref","first-page":"e077090","DOI":"10.1136\/bmj-2023-077090","volume":"383","author":"M Thursz","year":"2023","unstructured":"Thursz, M., and Lingford-Hughes, A. (2023). Advances in the understanding and management of alcohol-related liver disease. BMJ 383, e077090.","journal-title":"BMJ"},{"key":"2722_CR75","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg, H., Adolph, T.E., and Trauner, M. (2022). Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 34, 1700\u20131718.","journal-title":"Cell Metab"},{"key":"2722_CR76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00125-019-05040-3","volume":"63","author":"B Tramunt","year":"2020","unstructured":"Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.F., Montagner, A., and Gourdy, P. (2020). Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia 63, 453\u2013461.","journal-title":"Diabetologia"},{"key":"2722_CR77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-publhealth-032315-021606","volume":"37","author":"BC Truesdale","year":"2016","unstructured":"Truesdale, B.C., and Jencks, C. (2016). The health effects of income inequality: averages and disparities. Annu Rev Public Health 37, 413\u2013430.","journal-title":"Annu Rev Public Health"},{"key":"2722_CR78","doi-asserted-by":"crossref","first-page":"155248","DOI":"10.1016\/j.metabol.2022.155248","volume":"136","author":"L Valenzuela-Vallejo","year":"2022","unstructured":"Valenzuela-Vallejo, L., Guatibonza-Garc\u00eda, V., and Mantzoros, C.S. (2022). Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)\/ Fatty Liver Disease (FLD): are they already outdated and in need of supplementation? Metabolism 136, 155248.","journal-title":"Metabolism"},{"key":"2722_CR79","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jhep.2022.06.031","volume":"77","author":"LPM van Leeuwen","year":"2022","unstructured":"van Leeuwen, L.P.M., de Jong, W., Doornekamp, L., van Gorp, E.C.M., Wismans, P.J., and Goeijenbier, M. (2022). Exotic viral hepatitis: a review on epidemiology, pathogenesis, and treatment. J Hepatol 77, 1431\u20131443.","journal-title":"J Hepatol"},{"key":"2722_CR80","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.7150\/thno.55795","volume":"11","author":"F Wang","year":"2021","unstructured":"Wang, F., So, K.F., Xiao, J., and Wang, H. (2021). Organ-organ communication: the liver\u2019s perspective. Theranostics 11, 3317\u20133330.","journal-title":"Theranostics"},{"key":"2722_CR81","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.gastro.2023.05.050","volume":"165","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Huang, Y., Chase, R.C., Li, T., Ramai, D., Li, S., Huang, X., Antwi, S.O., Keaveny, A.P., and Pang, M. (2023). Global burden of digestive diseases: a systematic analysis of the global burden of diseases study, 1990 to 2019. Gastroenterology 165, 773\u2013783.e15.","journal-title":"Gastroenterology"},{"key":"2722_CR82","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","volume":"327","author":"AM White","year":"2022","unstructured":"White, A.M., Castle, I.J.P., Powell, P.A., Hingson, R.W., and Koob, G.F. (2022). Alcohol-related deaths during the COVID-19 pandemic. JAMA 327, 1704\u20131706.","journal-title":"JAMA"},{"key":"2722_CR83","doi-asserted-by":"crossref","first-page":"p1041","DOI":"10.1136\/bmj.p1041","volume":"381","author":"J Wise","year":"2023","unstructured":"Wise, J. (2023). Covid-19: WHO declares end of global health emergency. BMJ 381, p1041.","journal-title":"BMJ"},{"key":"2722_CR84","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","volume":"71","author":"J Xiao","year":"2019","unstructured":"Xiao, J., Wang, F., Wong, N.K., He, J., Zhang, R., Sun, R., Xu, Y., Liu, Y., Li, W., Koike, K., et al. (2019). Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol 71, 212\u2013221.","journal-title":"J Hepatol"},{"key":"2722_CR85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3727\/105221620X15952664091823","volume":"20","author":"J Xiao","year":"2020","unstructured":"Xiao, J., Wang, F., Wong, N.K., Lv, Y., Liu, Y., Zhong, J., Chen, S., Li, W., Koike, K., Liu, X., et al. (2020). Epidemiological realities of alcoholic liver disease: global burden, research trends, and therapeutic promise. gene expr 20, 105\u2013118.","journal-title":"gene expr"},{"key":"2722_CR86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12961-020-00560-6","volume":"18","author":"A Yegros-Yegros","year":"2020","unstructured":"Yegros-Yegros, A., van de Klippe, W., Abad-Garcia, M.F., and Rafols, I. (2020). Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives. Health Res Policy Sys 18, 47.","journal-title":"Health Res Policy Sys"},{"key":"2722_CR87","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/jgh.16257","volume":"38","author":"EL Yoon","year":"2023","unstructured":"Yoon, E.L., and Kim, W. (2023). Current and future treatment for alcoholic-related liver diseases. J Gastro Hepatol 38, 1218\u20131226.","journal-title":"J Gastro Hepatol"},{"key":"2722_CR88","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z.M., Golabi, P., Paik, J.M., Henry, A., Van Dongen, C., and Henry, L. (2023a). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347.","journal-title":"Hepatology"},{"key":"2722_CR89","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z.M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q.M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P.N., et al. (2019). Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196.","journal-title":"Lancet"},{"key":"2722_CR90","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","volume":"21","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z.M., Wong, G., Anstee, Q.M., and Henry, L. (2023b). The global burden of liver disease. Clin Gastroenterol Hepatol 21, 1978\u20131991.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2722_CR91","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41575-022-00729-0","volume":"20","author":"N Zabaleta","year":"2023","unstructured":"Zabaleta, N., Unzu, C., Weber, N.D., and Gonzalez-Aseguinolaza, G. (2023). Gene therapy for liver diseases \u2014 progress and challenges. Nat Rev Gastroenterol Hepatol 20, 288\u2013305.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2722_CR92","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","volume":"68","author":"S Zelber-Sagi","year":"2018","unstructured":"Zelber-Sagi, S., Ivancovsky-Wajcman, D., Fliss Isakov, N., Webb, M., Orenstein, D., Shibolet, O., and Kariv, R. (2018). High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol 68, 1239\u20131246.","journal-title":"J Hepatol"},{"key":"2722_CR93","doi-asserted-by":"crossref","first-page":"571","DOI":"10.21147\/j.issn.1000-9604.2018.06.01","volume":"30","author":"R Zheng","year":"2018","unstructured":"Zheng, R., Qu, C., Zhang, S., Zeng, H., Sun, K., Gu, X., Xia, C., Yang, Z., Li, H., Wei, W., et al. (2018). Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res 30, 571\u2013579.","journal-title":"Chin J Cancer Res"},{"key":"2722_CR94","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou, J., Zhou, F., Wang, W., Zhang, X.J., Ji, Y.X., Zhang, P., She, Z., Zhu, L., Cai, J., and Li, H. (2020). Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology 71, 1851\u20131864.","journal-title":"Hepatology"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-024-2722-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T13:06:53Z","timestamp":1737637613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-024-2722-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2722"],"URL":"https:\/\/doi.org\/10.1007\/s11427-024-2722-2","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}